Shares surged 9.5% in after-hours trading after Vera Therapeutics reported its first-ever product revenue and nearly doubled its full-year sales outlook — a result that crushed Wall Street estimates but still leaves the company deeply unprofitable as competition intensifies in the kidney-disease space.
Revenue That Nobody Expected This High
Vera posted $10.3 million in initial product revenue for the quarter, exceeding the consensus estimate of $5.1 million.
The drug received accelerated FDA approval on July 7, 2026, to treat IgA nephropathy — a chronic autoimmune kidney disease that can lead to organ failure. Management raised its full-year 2026 revenue guidance to $22–$25 million, up from $12–$15 million. That kind of upward revision just four months after launch signals genuine physician uptake, not just warehouse stocking. Roughly half of Q3 revenue reflected patient demand and half reflected inventory stocking by distributors , meaning Q4 should tilt more heavily toward real prescriptions.
700 Patients Started, but 160,000 Are Diagnosed
There are approximately 160,000 diagnosed IgA nephropathy patients in the U.S., roughly 75% of whom are commercially insured. With only ~700 patient start forms to date, Vera has barely scratched the surface. The company is targeting insurance coverage for 50% of U.S. lives by year-end , a milestone that would unlock broader prescribing and faster revenue ramp.
The Cash Math Is Still Brutal
Launch spending is running well ahead of sales: $61.4 million in Q3 selling and administrative costs versus $10.3 million in product revenue.
The net loss widened to $93.7 million for the quarter.
Vera ended September with $384 million in cash, drew $75 million on its debt facility in October, bringing pro forma liquidity to roughly $459 million — enough runway for now, but the burn rate demands sales acceleration.
A Competitor Is at the Door
Wedbush flagged caution about a potential competitor launch in December from Vertex Pharmaceuticals , which could pressure market share just as Vera is building momentum. Raymond James countered with an $87 price target and Strong Buy rating , arguing the launch trajectory justifies optimism. The divergence between a $29 bear target and an $87 bull target underscores a simple reality: at $32.60, the stock is priced for a single-product company that must prove it can scale revenue faster than it burns cash — before bigger rivals crowd the field.